Impact of radiation on host immune system in patients treated with chemoradiotherapy and durvalumab consolidation for unresectable locally advanced non-small cell lung cancer.
EDRIC
elective node irradiation
immunotherapy
lymphopenia
non-small cell lung cancer (NSCLC)
radiotherapy
tumor-draining lymph nodes (TDLN)
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
03
2023
accepted:
30
05
2023
medline:
3
7
2023
pubmed:
3
7
2023
entrez:
3
7
2023
Statut:
epublish
Résumé
The optimal modalities of radiotherapy when combining concurrent chemoradiation (CCRT) and immunotherapy (IO) for locally advanced non-small cell lung cancer (LA-NSCLC) remain to be determined. The aim of this study was to investigate the impact of radiation on different immune structures and immune cells in patients treated with CCRT followed by durvalumab. Clinicopathologic data, pre- and post-treatment blood counts, and dosimetric data were collected in patients treated with CCRT and durvalumab consolidation for LA-NSCLC. Patients were divided into two groups according to the inclusion (NILN-R+) or not (NILN-R-) of at least one non-involved tumor-draining lymph node (NITDLN) in the clinical target volume (CTV). Progression-free survival (PFS) and overall survival (OS) were estimated by the Kaplan-Meier method. Fifty patients were included with a median follow-up of 23.2 months (95% CI 18.3-35.2). Two-year PFS and 2-year OS were 52.2% (95% CI 35.8-66.3) and 66.2% (95% CI 46.5-80.1), respectively. In univariable analysis, NILN-R+ (hazard ratio (HR) 2.60, p = 0.028), estimated dose of radiation to immune cells (EDRIC) >6.3 Gy (HR 3.19, p = 0.049), and lymphopenia ≤ 500/mm The inclusion of at least one NITDLN station within the CTV was an independent factor for poorer PFS in the context of CCRT and durvalumab for LA-NSCLC. The optimal sparing of immune structures might help in achieving better synergy between radiotherapy and immunotherapy in this indication.
Sections du résumé
Background
UNASSIGNED
The optimal modalities of radiotherapy when combining concurrent chemoradiation (CCRT) and immunotherapy (IO) for locally advanced non-small cell lung cancer (LA-NSCLC) remain to be determined. The aim of this study was to investigate the impact of radiation on different immune structures and immune cells in patients treated with CCRT followed by durvalumab.
Material and methods
UNASSIGNED
Clinicopathologic data, pre- and post-treatment blood counts, and dosimetric data were collected in patients treated with CCRT and durvalumab consolidation for LA-NSCLC. Patients were divided into two groups according to the inclusion (NILN-R+) or not (NILN-R-) of at least one non-involved tumor-draining lymph node (NITDLN) in the clinical target volume (CTV). Progression-free survival (PFS) and overall survival (OS) were estimated by the Kaplan-Meier method.
Results
UNASSIGNED
Fifty patients were included with a median follow-up of 23.2 months (95% CI 18.3-35.2). Two-year PFS and 2-year OS were 52.2% (95% CI 35.8-66.3) and 66.2% (95% CI 46.5-80.1), respectively. In univariable analysis, NILN-R+ (hazard ratio (HR) 2.60, p = 0.028), estimated dose of radiation to immune cells (EDRIC) >6.3 Gy (HR 3.19, p = 0.049), and lymphopenia ≤ 500/mm
Conclusion
UNASSIGNED
The inclusion of at least one NITDLN station within the CTV was an independent factor for poorer PFS in the context of CCRT and durvalumab for LA-NSCLC. The optimal sparing of immune structures might help in achieving better synergy between radiotherapy and immunotherapy in this indication.
Identifiants
pubmed: 37397359
doi: 10.3389/fonc.2023.1186479
pmc: PMC10313116
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1186479Informations de copyright
Copyright © 2023 Pasquier, Chaltiel, Massabeau, Rabeau, Lebas, Lusque, Texier, Moyal, Mazières and Khalifa.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lung Cancer. 2021 Apr;154:36-43
pubmed: 33611224
Front Med China. 2007 Oct;1(4):381-5
pubmed: 24573930
J Clin Oncol. 2022 Apr 20;40(12):1301-1311
pubmed: 35108059
Lancet Oncol. 2020 Apr;21(4):581-592
pubmed: 32171429
Int J Radiat Oncol Biol Phys. 2021 Nov 15;111(4):936-948
pubmed: 34329738
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33028691
Cancers (Basel). 2021 Dec 08;13(24):
pubmed: 34944813
Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):337-43
pubmed: 19775827
Lancet Oncol. 2021 Apr;22(4):450-462
pubmed: 33794205
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Front Oncol. 2021 Apr 21;11:662236
pubmed: 33968769
Transl Lung Cancer Res. 2021 Apr;10(4):1999-2010
pubmed: 34012809
Radiother Oncol. 2017 Jul;124(1):1-10
pubmed: 28666551
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1084-1091
pubmed: 25035212
Ann Oncol. 2023 Jan;34(1):101-110
pubmed: 36522816
J Thorac Cardiovasc Surg. 2001 Oct;122(4):803-8
pubmed: 11581617
Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):346-355
pubmed: 31175902
Radiother Oncol. 2022 Mar;168:1-7
pubmed: 35033601
J Thorac Oncol. 2020 Oct;15(10):1624-1635
pubmed: 32553694
Am J Clin Oncol. 2007 Jun;30(3):239-44
pubmed: 17551299
Chest. 1990 May;97(5):1059-65
pubmed: 2331899
Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):323-332
pubmed: 28068240
Clin Cancer Res. 2018 Oct 15;24(20):5058-5071
pubmed: 29898992
Radiother Oncol. 2022 Sep;174:133-140
pubmed: 35870727
J Pathol Bacteriol. 1952 Oct;64(4):687-704
pubmed: 13000583
Nat Commun. 2022 Nov 16;13(1):7015
pubmed: 36385142
Semin Thorac Cardiovasc Surg. 2009 Winter;21(4):298-308
pubmed: 20226342
Biomed Res Int. 2013;2013:371819
pubmed: 23762840
J Radiat Res. 2017 Jan;58(1):86-105
pubmed: 27609192
Radiother Oncol. 2018 Apr;127(1):1-5
pubmed: 29605476
Cancer Invest. 2013 Mar;31(3):183-8
pubmed: 23432821
Cancer Cell. 2020 Nov 9;38(5):685-700.e8
pubmed: 33007259
JCI Insight. 2018 Dec 6;3(23):
pubmed: 30518694
Radiother Oncol. 2022 Feb;167:158-164
pubmed: 34942280
Radiat Oncol. 2016 Sep 21;11(1):124
pubmed: 27655339